Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work better for STK11 or KEAP1 mutated (SKmut) aNSCLC pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Nie, Wei, Gan, Lu, Wang, Xin, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Zhang, Ding, Chen, Shi-Qing, Lu, Jun, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Li, Chang-Hui, Yang, Ping, Xu, Mi–Die, Zhang, Xue-Yan, Zhong, Hua, Han, Bao-Hui
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7833760/
https://ncbi.nlm.nih.gov/pubmed/33537171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1865670
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars